The effect of the degree of hepatitis C related fibrosis on the responsiveness to PegIFNα2a Vs PegIFNα2b
Gina Gamal Naguib;
Abstract
Hepatitis C virus (HCV) infection is a major public health burden with an estimated 185 million anti-HCV positive individuals worldwide (Welzel et al.,2014). Alarming news is that 350, 000 people worldwide die from HCV-related disease every year (Gravitz,2011). Hepatitis C virus (HCV) is a leading cause of chronic liver disease,cirrhosis,and hepatocellular carcinoma,as well as the most common indication for liver transplantation in many countries (Chen& Morgan,2006).
An estimated 10%-15% of HCV-infected persons will advance to cirrhosis within the first 20 years. Persons with cirrhosis are at increased risk of developing HCC. An understanding of the natural history of hepatitis C is essential to effectively manage,treat,and counsel individuals with HCV infection (Chen& Morgan,2006).
Although blood screening and other preventive measures have reduced the incidence of HCV in some parts of the world,infection with this virus remains a significant worldwide health concern (Pawlotsky,2013).
This study was designed to assess the effect of degree of hepatitis C related fibrosis on the responsiveness to PegIFNα2a or PegIFNα2b in Egyptian patients.
All patients were subjected to history taking,laboratory investigations including RT-PCR for HCV and divided into two groups according to the type of interferon regimen given. Then patients were followed up during and after the course of treatment to monitor the response of treatment and its possible side effects.
Our study shows a non-significant correlation between type of interferon and virological response (p>0.05).
Our study shows a non-significant correlation between stages of fibrosis and virological response (p>0.05).
It also shows a non-significant correlation between basal liver enzymes,level of HCV viraemia and virological response (p>0.05).
Our study shows a non-significant correlation between drug-related side effects and interferon therapy (p>0.05) except anemia at 12 weeksand leukopenia at 24 weeks which are significant (p<0.05).
An estimated 10%-15% of HCV-infected persons will advance to cirrhosis within the first 20 years. Persons with cirrhosis are at increased risk of developing HCC. An understanding of the natural history of hepatitis C is essential to effectively manage,treat,and counsel individuals with HCV infection (Chen& Morgan,2006).
Although blood screening and other preventive measures have reduced the incidence of HCV in some parts of the world,infection with this virus remains a significant worldwide health concern (Pawlotsky,2013).
This study was designed to assess the effect of degree of hepatitis C related fibrosis on the responsiveness to PegIFNα2a or PegIFNα2b in Egyptian patients.
All patients were subjected to history taking,laboratory investigations including RT-PCR for HCV and divided into two groups according to the type of interferon regimen given. Then patients were followed up during and after the course of treatment to monitor the response of treatment and its possible side effects.
Our study shows a non-significant correlation between type of interferon and virological response (p>0.05).
Our study shows a non-significant correlation between stages of fibrosis and virological response (p>0.05).
It also shows a non-significant correlation between basal liver enzymes,level of HCV viraemia and virological response (p>0.05).
Our study shows a non-significant correlation between drug-related side effects and interferon therapy (p>0.05) except anemia at 12 weeksand leukopenia at 24 weeks which are significant (p<0.05).
Other data
| Title | The effect of the degree of hepatitis C related fibrosis on the responsiveness to PegIFNα2a Vs PegIFNα2b | Other Titles | تأثير درجة التليف ذات الصلة التهاب الكبد (سي) على الاستجابة لل PegIFNα2a مقابلPegIFNα2b | Authors | Gina Gamal Naguib | Issue Date | 2015 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.